Cramer Pamela J.

CHRO Pamela Cramer sold 22,866 shares (22.9K) across 2 transactions for $2,263,825.81 ($2.3M) at blended $99.00, reducing holdings 52.3%

Pamela Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, executed 2 separate sales totaling 22,866 shares for $2,263,825.81, reducing her holdings from 43,680 shares to 20,814 shares (a 52.3% reduction). The company is unprofitable with net income of $-52,904,000.00 against revenue of $51,298,000.00 for the latest quarter, though it showed strong annual revenue growth of 68.1%. Notably, Cramer's prior 5 sales at this ticker all resulted in positive 90-day returns, indicating the stock rose after she sold; none of those prior trades were well-timed at the 90-day mark. This filing reflects a substantial liquidation of her position; investors should monitor whether the stock's current price of $97.92 (14.0% below the 52-week high) represents value or signals continued headwinds at an unprofitable but fast-growing company.

CHRO Pamela Cramer sells 15,572 shares in 3 transactions for $1,201,062.21; -44.8% of holdings; stock +33.7% (30d), +45.6% (90d).

Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, executed 3 separate sales on 2025-07-09 totaling 15,572 shares for $1,201,062.21, reducing her holdings by 44.8% from 34,781 to 19,209 shares. The timing follows a strong run: RYTM has gained +33.7% over the prior 30 days and +45.6% over the prior 90 days, placing the stock -2.6% from its 52-week high of $89.04. Her prior 5 trades at RYTM show mixed timing outcomes—only 1 of 5 achieved negative 90-day returns (well-timed sells); the most recent prior sale in November 2024 resulted in a -6.1% 90-day return, but the four April 2025 sales all showed positive returns after the fact. The company is unprofitable (full-year net income was negative) despite strong revenue growth of 68.1% year-over-year, a dynamic that warrants monitoring for alignment between operational momentum and shareholder returns.

CHRO Cramer sells 20,760 shares in 4 transactions at $58.36–$62.00, liquidating 51.9% of holdings for $1.2M

Pamela J. Cramer, Chief Human Resources Officer, executed four separate sales on 2025-04-08 totaling 20,760 shares (20.8K shares) for $1,248,490.37 at prices ranging from $58.36 to $62.00, reducing her holdings from 39,969 shares to 19,209 shares—a net reduction of 51.9%. The blended average sale price of $60.14 sits above the current price of $57.83 (-14.1% from the 52-week high of $67.33), suggesting the sales executed during a period of relative strength. Rhythm Pharmaceuticals is unprofitable on a full-year basis (net income of $-43,641,000.00) while generating $33,251,000.00 in latest-quarter revenue with 68.1% annual growth, a profile typical of pre-profitability biotech firms. Cramer's same-ticker history at RYTM shows mixed timing: 2 of 5 prior sells posted negative 90-day returns (well-timed entry ahead of declines), while 2 posted positive 90-day returns (poorly timed ahead of rallies), with no clear pattern of predictive accuracy at this specific ticker.

CHRO Pamela Cramer sells 9,375 shares at avg $62.50; stock now at $67.33 after +41.1% 30d rally

Pamela J. Cramer, Chief Human Resources Officer, executed two separate sales on 2024-11-06 and 2024-11-07, selling 4,687 shares at $60.00 ($281,220.00) and 4,688 shares at $65.00 ($304,720.00) for a combined total of 9,375 shares at a blended average price of $62.50. The sales reduced her holdings by 41.0%, from 22,875 to 13,500 shares. The stock has since appreciated to $67.33, now at its 52-week high, and has gained 41.1% over the prior 30 days and 48.8% over 90 days. Her prior three sales at RYTM occurred during less favorable conditions: two in August 2024 saw subsequent 30-day gains of 9.1% and 8.0% respectively (90-day gains of 41.6% and 40.1%), while a March 2024 sale saw a 30-day decline of 2.8% followed by a 90-day gain of 5.0%. The company remains unprofitable (net income of $-43.6M) despite strong annual revenue growth of 227.6%, with latest quarterly revenue of $33.3M. Her cross-ticker selling history shows an average 90-day return after sales of 28.9% with no well-timed outcomes at the 90-day mark.

CHRO Cramer sells 49,006 shares (78.4% of holdings) at $45.15 avg; stock -14.7% from 52-week high, firm unprofitable.

Pamela J. Cramer, Chief Human Resources Officer, executed 2 separate sales totaling 49,006 shares for $2,212,497.93, reducing her stake from 62,506 to 13,500 shares. This represents a -78.4% reduction in her holdings. The sales occurred at a blended average price of $45.15, near the current price of $45.97 but well below the 52-week high of $53.89. Rhythm Pharmaceuticals remains unprofitable with net income of $-32,261,000.00 against revenue of $29,078,000.00 in the latest quarter, though the company showed strong annual revenue growth of +227.6%. Cramer's prior sale at this ticker on 2024-03-19 showed a -2.8% 30-day return and +5.0% 90-day return, indicating her prior timing was not well-executed; the stock subsequently recovered. Investors should monitor whether this large reduction in executive equity stake reflects evolving confidence levels or scheduled rebalancing, particularly given the company's ongoing path to profitability despite revenue momentum.